The abstract is read at the publisher; the summary is JClub's.
Non-invasive tests can predict clinically meaningful decompensation outcomes in compensated advanced chronic liver disease with prognostic accuracy comparable to hepatic venous pressure gradient (HVPG) measurement.
- Why it matters: Risk stratification has relied on static CSPH thresholds, yet clinicians need dynamic, individualized prediction of decompensation and liver-related death beyond surrogate surrogates.
- What they did: The approach uses NIT-based direct risk assessment, including elastography, models such as ANTICIPATE and Non-Invasive CSPH Estimated Risk, and blood-based scores like the Portal Hypertension Decompensation Score.
- The result: Standardizing outcome-based endpoints around classical portal hypertension decompensation events supports wider clinical adoption and enables continuous longitudinal reassessment of patient risk and treatment response.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.